The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
 
Jaume Mora
Consulting or Advisory Role - Bristol-Myers Squibb; Ymabs Therapeutics Inc
Research Funding - Roche/Genentech (Inst)
 
Godfrey Chi-Fung Chan
Leadership - Pangenia; Xellera Therapeutics
Consulting or Advisory Role - Pangenia; Xellera Therapeutics
Speakers' Bureau - Pangenia; Xellera Therapeutics
Patents, Royalties, Other Intellectual Property - Pangenia; Xellera Therapeutics
 
Daniel A. Morgenstern
Consulting or Advisory Role - Bayer; Newlink Genetics; Roche
Speakers' Bureau - EUSA Pharma
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ymabs Therapeutics Inc
 
Karsten Nysom
Honoraria - Bayer
Consulting or Advisory Role - Bayer
 
Melissa K Bear
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Lene Worsaae Dalby
Employment - Y-mAbs Therapeutics
Stock and Other Ownership Interests - Y-mAbs Therapeutics
 
Steen Lisby
Employment - Y-mAbs Therapeutics
Stock and Other Ownership Interests - Y-mAbs Therapeutics
Patents, Royalties, Other Intellectual Property - Genmab; Y-mAbs Therapeutics
Travel, Accommodations, Expenses - Y-mAbs Therapeutics (I)
 
Brian H. Kushner
No Relationships to Disclose